Specific vaginal and gut microbiome and the anti-tumor effect of butyrate in women with cervical cancer.

This is the authors' abstract. We don't add key points for this paper.

5529 Background: To investigate the vaginal and gut microbes changes during the carcinogenesis of cervical and the auxiliary diagnostic value of microbial markers. To investigate the effect of microbiome-specific metabolites butyric on cervical cancer cells. Methods: We studied 416 vaginal 16S rRNA sequencing data and 116 gut data. Reads were processed using VSEARCH. We used Shannon index, Chao1 index, Simpson diversity index, Beta diversity index, LEfSe analysis, co-abundance network analysis and KEGG enrichment analysis to explore microbiome differences between groups. We constructed random forest models based on genus and validated the models to test their diagnostic effectiveness. Finally, we used the cell counting kit-8 (CCK-8) method to detect cell proliferation capacity and flow cytometry to detect apoptosis and induction of cell cycle progression. Results: Compared to the non-cancerous population, patients with cervical cancer had unique microbial community characteristics in both vaginal and gut ecological niches. Our predictive model based on genus in two ecological regions achieved high accuracy in the diagnosis of cervical cancer (vaginal model AUC=91.58%; gut model AUC=99.95%). Potential functional pathways analysis indicated significant differences between the normal women microbiomes and cervical cancer women microbiomes. Butyric inhibited cervical cancer cell proliferation in a concentration-dependent manner and promoted apoptosis of cancer cells. Conclusions: Significant differences were found in vaginal and gut microbes in patients with cervical cancer compared to the non-cancerous population, and the microflora is involved in cervical carcinogenesis. The prediction models constructed at the genus level in both ecological sites have good diagnostic value for cervical cancer. Microorganisms may be involved in cervical cancer progression in a metabolite-dependent way, and targeting butyric may provide therapeutic options for cervical cancer.